Jump-starting the immune system: prime-boosting comes of age.
about
Potentiating cancer immunotherapy using an oncolytic virusEbolavirus vaccines for humans and apesCombined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 proteinAn Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for FinfishCD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive VaccinesPrime-boost approaches to tuberculosis vaccine developmentUse of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccinationCurrent progress in the development of therapeutic vaccines for chronic hepatitis B virus infectionImmunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse modelsStrategic Priming with Multiple Antigens can Yield Memory Cell Phenotypes Optimized for Infection with Mycobacterium tuberculosis: A Computational StudyPartially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.Immunology of Gut Mucosal VaccinesBovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus.Is there a role for plant-made vaccines in the prevention of HIV/AIDS?HIV vaccine acceptability among communities at risk: the impact of vaccine characteristicsExploiting cross-priming to generate protective CD8 T-cell immunity rapidly.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesSystemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challengePrimed immune responses to gram-negative peptidoglycans confer infection resistance in silkworms.Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routesPrime-boost immunization using a DNA vaccine delivered by attenuated Salmonella enterica serovar typhimurium and a killed vaccine completely protects chickens from H5N1 highly pathogenic avian influenza virus.Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability.Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.Protection against aerosolized Yersinia pestis challenge following homologous and heterologous prime-boost with recombinant plague antigens.Memory CD8+ T cells protect dendritic cells from CTL killing.Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity.The longevity of memory CD8 T cell responses after repetitive antigen stimulationsTowards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategyRepetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation.IL-12 is required for mTOR regulation of memory CTLs during viral infection.Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein DImpact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivoModulating numbers and phenotype of CD8+ T cells in secondary immune responses.HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.Progress towards an effective syphilis vaccine: the past, present and future.
P2860
Q24628810-697DFF3C-CA27-43F5-9CD9-6191919F4878Q24631696-13016C1C-1510-48FD-AF97-FE36ED5C07E1Q24813809-DD62651E-05C3-4CFA-AE0C-C39C54E41939Q26777943-C2595C04-0906-49A8-9AA8-94DCB94E8FE8Q27014949-7835624B-88BA-45CF-93E4-017032349FFEQ27024526-A435E895-3C06-460F-BB0F-AED980349043Q27314609-95113E1B-E71A-4238-8B2A-3AF4053982B2Q28076279-1B45F8EB-B546-49D2-8644-8BD38630E49DQ28083154-0862DCC3-8ED6-42C6-A470-4BBD5E08D067Q28603191-6093488E-B996-4BB4-B397-E34500B40483Q28742762-283168EC-ED0D-4965-B3A3-B52FB3337408Q28972559-248024B9-2BAE-43BB-8C91-45CCE5822328Q30229074-EDBABA75-FB89-421E-A79A-9B24F2D55EA0Q30350670-C7CD115B-862F-4F16-8E0A-5C178899FDC1Q30352116-98D60DD5-33A9-46AB-83EC-6CCAC4959254Q30391225-0BDBCDF6-0040-470A-BC47-B3DF41E32F93Q30427591-0E1EA958-1E96-4B30-AA88-AE14B5BC220BQ33551402-CBE3F7E6-4350-403F-A433-8E598623E0E0Q33619596-61B07C24-CBA6-43E5-BBB1-B66C3535BF1FQ33713083-09081C74-6C9B-468F-BA5C-88091CF65732Q33743758-8D9B984E-267F-4F47-A4B6-9CEBCAB6E60DQ33768698-1CEB3DB2-E656-4463-8688-719A3EBC3215Q33824782-CED5EF80-8940-4372-ABC3-4A7AF3B9DA00Q33855619-E507A96C-BC55-41B1-BFFC-6A608788DA71Q33881234-692D83AC-BD78-4860-8ED3-F7F6AFC07621Q33940220-00BF60D9-8D51-4420-8DCF-AA3E1F536E4DQ33946563-E5DA002A-46C6-463E-BE3D-922929DE3921Q34000039-D6C3EF60-40E7-4C44-969A-CB1B2EE2534AQ34000201-24C9DB30-86C9-45E9-AD89-54F6ED1D16ECQ34024434-763E55C5-EC7F-412C-BA15-EEEEC1EEB3E1Q34025527-4C67B50D-17A0-4DD7-B393-517A156E66A3Q34028816-5952A884-0342-4032-9EF6-86316C07C171Q34143415-110938E1-1BED-4838-9906-0C2901660835Q34189966-7E34E1D0-EDA1-4820-8ACE-929F10733DD5Q34296144-8007A316-DDF0-453E-908A-9C3715325CC0Q34298763-5FE473C7-58E7-48BB-9592-D35857FAC6B2Q34357154-B142EEB2-8A47-4436-888F-C391545E058BQ34375565-8CB1CBFE-8C27-4FEE-BAC0-1023489D80E8Q34434814-CB921FB4-BFC7-4DDD-AD3D-3ED6600256F9Q34490385-4EBE36D7-DD2B-426B-8C53-A83DFDA4163F
P2860
Jump-starting the immune system: prime-boosting comes of age.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Jump-starting the immune system: prime-boosting comes of age.
@ast
Jump-starting the immune system: prime-boosting comes of age.
@en
type
label
Jump-starting the immune system: prime-boosting comes of age.
@ast
Jump-starting the immune system: prime-boosting comes of age.
@en
prefLabel
Jump-starting the immune system: prime-boosting comes of age.
@ast
Jump-starting the immune system: prime-boosting comes of age.
@en
P356
P1433
P1476
Jump-starting the immune system: prime-boosting comes of age.
@en
P2093
David L Woodland
P304
P356
10.1016/J.IT.2003.11.009
P577
2004-02-01T00:00:00Z